Clinical Trial Update: MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer [NA]

View source ↗

Summary

A clinical-trial update shows that MucoLox Formulation, designed to mitigate oral mucositis in head and neck cancer patients, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis

Drugs mentioned

• MucoLox Formulation (MucoLox)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Mucositis Oral, Head and Neck Cancer | NA | Status: TERMINATED